QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A10F0BAC488BB1596C5F0CE4F667FB3F;jsessionid=4604EAF85061B7D2112CE838C4F764A6;jsessionid=5C7888C1C796D7E3ECF861FCDD776DA6;jsessionid=FB7B545F5070CABEE2B39869C24668B4;jsessionid=750A7E69A1D597B481F8AE36B0A2EC55;jsessionid=8F28E24925E013490E10D44BF44F3CF4;jsessionid=7EF3FE152B5ED7EE71DCC218A258705E;jsessionid=29AD522CE17202BAD3AFDF25AEBFD377;jsessionid=8F058549590B287139B2A5803003080A;jsessionid=7A3628ED4395CFA032A2E12ABAC1C7E5 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A10F0BAC488BB1596C5F0CE4F667FB3F;jsessionid=4604EAF85061B7D2112CE838C4F764A6;jsessionid=5C7888C1C796D7E3ECF861FCDD776DA6;jsessionid=FB7B545F5070CABEE2B39869C24668B4;jsessionid=750A7E69A1D597B481F8AE36B0A2EC55;jsessionid=8F28E24925E013490E10D44BF44F3CF4;jsessionid=7EF3FE152B5ED7EE71DCC218A258705E;jsessionid=29AD522CE17202BAD3AFDF25AEBFD377;jsessionid=8F058549590B287139B2A5803003080A;jsessionid=7A3628ED4395CFA032A2E12ABAC1C7E5